413 related articles for article (PubMed ID: 36719097)
61. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R; Tu W; Farjat AE; Farag YMK; Toto R; Kaul S; Lawatscheck R; Rohwedder K; Ruilope LM; Rossing P; Pitt B; Filippatos G; Anker SD; Bakris GL;
Ann Intern Med; 2023 Dec; 176(12):1606-1616. PubMed ID: 38048573
[TBL] [Abstract][Full Text] [Related]
62. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.
Chen X; Li X; Zhang K; Lian K; Zhang W; Song Y; Kan C; Zhang J; Han F; Sun X; Guo Z
Clin Exp Nephrol; 2024 Feb; 28(2):125-135. PubMed ID: 37847437
[TBL] [Abstract][Full Text] [Related]
63. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Doggrell SA
Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
[No Abstract] [Full Text] [Related]
64. The mineralocorticoid receptor in chronic kidney disease.
Barrera-Chimal J; Jaisser F; Anders HJ
Br J Pharmacol; 2022 Jul; 179(13):3152-3164. PubMed ID: 34786690
[TBL] [Abstract][Full Text] [Related]
65. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
66. Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
Solis-Herrera C; Triplitt C
Diabetes Obes Metab; 2024 Feb; 26(2):417-430. PubMed ID: 37885354
[TBL] [Abstract][Full Text] [Related]
67. A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift.
Epstein M
Diabetes Ther; 2022 Apr; 13(4):583-588. PubMed ID: 35294746
[TBL] [Abstract][Full Text] [Related]
68. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes.
Ashjian E; Clarke M; Pogue K
Am J Health Syst Pharm; 2023 Nov; 80(23):1708-1721. PubMed ID: 37632460
[TBL] [Abstract][Full Text] [Related]
69. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
[TBL] [Abstract][Full Text] [Related]
70. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
Gohda T; Murakoshi M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
[TBL] [Abstract][Full Text] [Related]
71. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
Raj R
Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
[TBL] [Abstract][Full Text] [Related]
72. Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Rossing P; Filippatos G; Agarwal R; Anker SD; Pitt B; Ruilope LM; Chan JCN; Kooy A; McCafferty K; Schernthaner G; Wanner C; Joseph A; Scheerer MF; Scott C; Bakris GL;
Kidney Int Rep; 2022 Jan; 7(1):36-45. PubMed ID: 35005312
[TBL] [Abstract][Full Text] [Related]
73. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
[TBL] [Abstract][Full Text] [Related]
74. Finerenone: First Approval.
Frampton JE
Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
[TBL] [Abstract][Full Text] [Related]
75. Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus.
Rastogi A; Weir MR
J Diabetes Complications; 2023 Aug; 37(8):108515. PubMed ID: 37356235
[TBL] [Abstract][Full Text] [Related]
76. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
Rosas SE; Ruilope LM; Anker SD; Pitt B; Rossing P; Bonfanti AAC; Correa-Rotter R; González F; Munoz CFJ; Pergola P; Umpierrez GE; Scalise A; Scott C; Lawatscheck R; Joseph A; Bakris GL;
Kidney Med; 2023 Oct; 5(10):100704. PubMed ID: 37745646
[TBL] [Abstract][Full Text] [Related]
77. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
78. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666
[TBL] [Abstract][Full Text] [Related]
79. Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases.
Chen W; Zheng L; Wang J; Lin Y; Zhou T
Front Endocrinol (Lausanne); 2023; 14():1320603. PubMed ID: 38174337
[TBL] [Abstract][Full Text] [Related]
80. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
Verma A; Patel AB
Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
